



## Faculty Disclosures

*The following types of relationships may be deemed relevant include:*

1. *Advisor or review panel member*
2. *Consultant*
3. *Employee*
4. *Officer or Board Member*
5. *Grant/research support*
6. *Speaker/honoraria includes speakers bureau, symposia, and expert witness*
7. *Independent contractor*
8. *Executive role and/or ownership interest*
9. *Royalties and/or patient beneficiary*
10. *Intellectual property/patents*
11. *Stock options or bond holdings in a for-profit corporation or self-directed pension plan*
12. *Private investigator*
13. *Expert witness*
14. *Equity interest*
15. *Other: specify details*

*All of the relevant financial relationships listed for the meeting faculty have been mitigated.*

### **Askanase, Anca, MD, MPH**

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Speaker

Disclosure: AbbVie/Abbott, 2 (Ongoing); Amgen, 1 (Ongoing); AstraZeneca, 2 (Ongoing); biogen, 5 (Ongoing); Bristol-Myers Squibb(BMS), 1 (Ongoing), 5 (Ongoing); Cabaletta, 5 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Idorsia, 5 (Ongoing); Pfizer, 5 (Terminated); Sanofi, 5 (Ongoing); UCB, 5 (Ongoing)

### **Bolster, Marcy, MD**

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Faculty/Planner

Disclosure: Prometheus, 5 (Ongoing)

***Dall’Era, Maria, MD***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Speaker

Disclosure: AstraZeneca, 2 (Ongoing); Aurinia, 2 (Ongoing); GlaxoSmithKlein, 2 (Ongoing), 5 (Ongoing); Janssen, 1 (Ongoing)

***Duarte-Garcia, Ali, MD, MSc***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Moderator

Disclosure: No financial relationships with ineligible companies to disclose

***Ferreira, Carlos***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

***Gardner, Gregory, MD, MACP***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Session Coordinator

Disclosure: No financial relationships with ineligible companies to disclose

***Oquendo, Clarissa***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

***Ross, Sharon***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

***Rovin, Brad, MD***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Moderator

Disclosure: Alexion, 2 (Ongoing); Artivabio, 2 (Ongoing); AstraZeneca, 2 (Ongoing), 5 (Ongoing); Aurinia, 2 (Ongoing), 5 (Ongoing); Biogen, 2 (Ongoing); F. Hoffmann-La Roche Ltd, 2 (Ongoing); Genentech, 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Kyverna, 2 (Ongoing); Novartis, 2 (Ongoing)

***Sammaritano, Lisa, MD***

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Scipio, Cheyenne**

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

**Son, Mary Beth, MD**

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Speaker

Disclosure: No financial relationships with ineligible companies to disclose

**Stanley, Myria, MS, DES**

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Planner

Disclosure: No financial relationships with ineligible companies to disclose

**Volkman, Elizabeth, MD, MS**

Scientific Session: ACR Convergence Replay 2024: 2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

Role: Clinical Chair

Disclosure: Boehringer-Ingelheim, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing);

GlaxoSmithKlein(GSK), 2 (Ongoing); Horizon, 5 (Ongoing); Prometheus, 5 (Ongoing)